Colivelin

Colivelin was created by attaching activity dependent neurotrophic factor (ADNF) to the N terminus of AGA-(C8R)HNG17, a strengthened analog of humanin, the short mitochondrial derived peptide first identified from an Alzheimer disease brain.

The fusion lowered the effective neuroprotective concentration to the femtomolar range, roughly a hundred fold more potent than the humanin derivative alone, and suppressed cell death from familial Alzheimer genes and amyloid beta in vitro while rescuing spatial working memory deficits in mice. Mechanistically colivelin engages two parallel prosurvival pathways: an ADNF driven calcium and calmodulin dependent protein kinase IV arm and a humanin driven STAT3 arm, a dual signaling design that underlies its potency and breadth.

In an amyotrophic lateral sclerosis mouse model, intracerebroventricular colivelin improved motor performance and prolonged survival with increased motor neuron survival in the spinal cord, extending its interest beyond dementia to motor neuron disease. Colivelin remains a laboratory neuroprotective peptide. It is not approved, has not undergone controlled human trials, and its short peptide nature raises the usual challenges of stability and delivery. It is best regarded as a mechanistic tool and drug candidate rather than a usable nootropic.

There is no established human safety profile; colivelin has not gone through clinical trials, so tolerability, immunogenicity, pharmacokinetics, and long-term effects in people are unknown. In rodent studies it was generally well tolerated at the doses used, including chronic intranasal and intraperitoneal administration, without prominent reported toxicity, but those studies were designed around efficacy, not formal safety endpoints. Because the mechanism amplifies STAT3 and other pro-survival, anti-apoptotic pathways, a reasonable theoretical concern is that broad, sustained anti-apoptotic signaling could be undesirable in tissues where apoptosis is protective (for instance in the context of cancer surveillance); this has not been studied for colivelin specifically. Anyone considering it should treat it as an unapproved research chemical with no medical oversight data behind it.

Colivelin was developed in the mid-2000s by a Japanese group centered at Keio University (Aiso, Nishimoto, Chiba, Matsuoka and colleagues) as part of a program to improve on humanin, an endogenous mitochondrial-derived peptide discovered from a surviving region of an Alzheimer's brain. Humanin protected neurons but only at high concentrations, so the team iterated derivatives and then fused the strongest one, AGA-(C8R)HNG17, to the ADNF-9 fragment. The 2005 Journal of Neuroscience paper introduced colivelin and its femtomolar activity against Alzheimer-relevant insults. Follow-up papers through 2006 to 2009 extended it to an ALS mouse model, intranasal memory rescue, and fetal alcohol neuroprotection, and later work (2017 to 2019) revisited it in APP/PS1 Alzheimer mice and in ischemic stroke. It never advanced into human clinical development and remains a laboratory neuroprotection tool.

Among neuroscientists studying humanin and mitochondrial-derived peptides, colivelin is respected as the most potent humanin-family neuroprotectant and a useful probe for STAT3-dependent survival signaling. It is frequently cited in that niche literature. In the broader research-chemical and peptide community it is far less known than the popular nootropic peptides; it shows up mainly as a specialty catalog item for lab use rather than as something with a following. There is no credible body of human experience or anecdote, and reputable sources describe it as investigational only.